Bairu Cheng
Biographic Data
| ID | 7263333 |
|---|---|
| NAME | Bairu Cheng |
| GIVEN NAMES | Bairu |
| FAMILY NAME | Cheng |
| SIGNATURE | CHENG B |
| AFFILIATIONS | Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
A systematic review and meta-analysis of randomized controlled trials on the efficacy of Shensong Yangxin capsule for recurrence of atrial fibrillation after catheter ablation
Ethnopharmacological relevance Shensong Yangxin (SSYX) capsule, a well-known Chinese patent medicine, is widely applied in the treatment of atrial fibrillation (AF). Aim of the study: To determine the efficacy and safety of SSYX as adjunctive therapy on recurrence after ablation in AF patients. Materials and methods A systematic search was conducted across eight databases to identify randomized controlled trials (RCTs) involving SSYX therapy afte…
Shenlian-Fumai formula attenuates ventricular arrhythmias via modulating sodium channel function in heart failure mice
SLFM exhibits antiarrhythmic and cardioprotective effects in HF by regulating sodium channel function and CaMKII signaling, highlighting its potential as a therapeutic option for HF-related VAs. However, all data were obtained from a single batch of SLFM, limiting generalizability and requiring validation with additional batches and harvest years
Efficacy and safety of Qiliqiangxin capsule as adjunctive therapy in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials
No prominent works on this page.
A systematic review and meta-analysis of randomized controlled trials on the efficacy of Shensong Yangxin capsule for recurrence of atrial fibrillation after catheter ablation
Ethnopharmacological relevance Shensong Yangxin (SSYX) capsule, a well-known Chinese patent medicine, is widely applied in the treatment of atrial fibrillation (AF). Aim of the study: To determine the efficacy and safety of SSYX as adjunctive therapy on recurrence after ablation in AF patients. Materials and methods A systematic search was conducted across eight databases to identify randomized controlled trials (RCTs) involving SSYX therapy afte…
Shenlian-Fumai formula attenuates ventricular arrhythmias via modulating sodium channel function in heart failure mice
SLFM exhibits antiarrhythmic and cardioprotective effects in HF by regulating sodium channel function and CaMKII signaling, highlighting its potential as a therapeutic option for HF-related VAs. However, all data were obtained from a single batch of SLFM, limiting generalizability and requiring validation with additional batches and harvest years
Efficacy and safety of Qiliqiangxin capsule as adjunctive therapy in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials
Cardiac electrophysiology and arrhythmias (3 works) · Adverse effect (2 works) · Cardiac Fibrosis and Remodeling (2 works) · Cardiac function curve (2 works) · Heart failure (2 works) · Randomized controlled trial (2 works) · Ablation (1 works) · Atrial fibrillation (1 works) · Atrial Fibrillation Management and Outcomes (1 works) · Capsule (1 works)